AVB and ABV: Residual Cannabinoids, Analysis, and the Limits of Current Knowledge
Short answer: AVB or ABV refers to already vaped plant material. Cannabinoids may remain in it. However, the residual quantity cannot be reliably calculated from colour, previous temperature setting or duration of use. Without appropriate analysis, a precise potency figure is not justified.
What do AVB and ABV mean?
The abbreviations are used colloquially for “Already Vaped Bud” and “Already Been Vaped” respectively. They refer to the material that remains in the chamber after use. The term documents a processing step, but not a standardised chemical state.
Two samples can share the same brown hue yet originate from different products and processes. Furthermore, the previous display setting does not describe every temperature within the material. AVB is therefore not a uniform ingredient with a fixed content.
The terms “spent” and “fully extracted” should also be distinguished. A completed device cycle does not prove the complete removal of all cannabinoids or other constituents.
What does a mass balance reveal about residues?
Device research can account for several fractions: starting material, collected aerosol, plant residue and deposits within the system. This breakdown explains why observed delivery cannot be determined from colour alone.
The Lanz method box describes one such device trial. Its results apply to defined materials and protocols. They do not provide a general table by which every brown sample still contains a fixed proportion of its original THC.
In particular, the earlier residual content ranges of 10–30 per cent and the temperature-dependent estimation series have been removed. Without appropriate evidence, these figures convey a certainty that does not exist for unknown residual samples.
Why is colour not a potency test?
Colour is a visual characteristic. Quantitative substance analysis requires a selective method, a representative sample and appropriate calibration. These prerequisites are not met by a photograph taken in daylight or a colour chart.
The fact that darker material may have been heated more intensely does not mean that a particular colour corresponds to a known THC concentration. Visible charring likewise cannot be converted into an exact residual content.
The following overview separates available observations from the evidence actually required. It is not a table for calculating an intake quantity.
| Observation | What it documents | What remains open |
|---|---|---|
| Brown material | Visible condition after heating | Residual quantities of individual compounds |
| High previous setting | Device set point | Profile within the material and complete release |
| Little aroma | Sensory impression | Completeness of terpene loss |
| Known starting content | Composition before use | Change caused by the specific process |
| Laboratory analysis of the residual sample | Measured composition of this sample | Individual uptake and effect |
The decisive boundary therefore remains between observation and measurement. An additional decimal place in a calculation cannot substitute for missing baseline data.
Is AVB always fully decarboxylated?
Heating can promote the conversion of acidic cannabinoids. However, complete reaction conversion is not an automatic property of every previously used sample. Time, temperature profile, and matrix must all be taken into account.
Decarboxylation and extraction are also distinct processes. A compound may have been converted and yet remain in the residual material. Conversely, an observed release does not permit a complete statement about all precursors still present.
The earlier blanket assertion that “decarboxylation is complete” has therefore been corrected. The background article explains the chemical distinction.
What do terpenes tell us about the residual sample?
A weak or altered aroma is not a complete terpene profile. Different compounds may behave differently. A mere list of boiling points is insufficient to derive all remaining constituents from the device’s operating cycle.
A subsequent treatment with water is likewise not a validated potency or contaminant standard. If the flavour is altered, it does not follow that the remaining sample is chemically well-characterised or cleared for any particular use.
The terpene audit provided does not validate recipes, shelf-life values, or medical dosages for AVB. This gap in the evidence base should not be filled with anecdotal values that are subsequently presented as if they were laboratory findings.
Why are calculations based on the original THC content unreliable?
Such a calculation requires not only the starting content but also the fraction actually remaining. If this proportion is estimated, the result is likewise an estimate. A blanket assumption of, for example, one fifth of the original content does not become a measured value by virtue of being inserted into a calculation.
With pooled leftover samples, additional uncertainties arise: different batches, varying processes, storage duration, and undocumented mixing. An analysis of a single fresh sample does not automatically describe the entire supply.
This version therefore contains no dose–effect table or guide that derives a reproducible intake from an unknown residual potency. A small visible quantity is not a reliable measure of an absorbed dose.
Why is oral ingestion different from inhalation?
Poyatos and colleagues evaluated 26 studies on oral administration of cannabis and THC preparations. Peak concentration and time to peak differed substantially between individuals and dosage forms. Baked goods and oils in particular showed variable profiles. The review is limited to one database and heterogeneous primary studies; nevertheless, the variability is a central finding relevant to already vaped bud (AVB). Poyatos et al. (2020)
The NIDA study compared smoked, vaporized, and oral cannabis administration within the same group of 20 individuals. Blood analyses revealed different concentration–time profiles and metabolite patterns following oral ingestion. These findings describe standardised study products, not home-prepared AVB preparations. Newmeyer et al. (2016)
A delayed onset can make it difficult to judge subjectively whether absorption is complete. No universally safe re-dosing threshold after a given number of minutes can be derived from these data. An early absence of perceptible effect is not analytical evidence of low potency. Poyatos et al. (2020)
What do data show on acute problems with edibles?
Monte and colleagues retrospectively examined emergency department cases. Of 9.973 screened cannabis-related visits, 2.567 were attributed at least in part to cannabis. Edible products were more frequently associated with certain acute intoxication, psychiatric, and cardiovascular complaints; inhaled use was more frequently associated with hyperemesis. Monte et al. (2019)
This study does not constitute a risk ratio for every individual exposure. The emergency department captures a selected population, and an accurate count of all exposures in the wider population as a denominator is absent. It supports the claim that oral products may present a different acute problem profile. It provides neither a direct AVB comparison nor a reliable ranking of all preparations.
A further analysis of the NIDA cohort examined divided attention and psychophysical tasks, amongst other measures. The fact that these were the same 20 individuals as in the pharmacokinetic papers must be taken into account: three publications do not constitute threefold independent confirmation here. Newmeyer et al. (2017) Newmeyer et al. (2016) Newmeyer et al. (2017)
What information would be needed for a reliable assessment?
| Question | What a useful source would need to include |
|---|---|
| Starting material | Analysed composition, not the strain name alone |
| Heating | Device, actual protocol, and documentation of the sample |
| Residual content | Representative laboratory analysis with measurement uncertainty |
| Preparation | Known distribution of constituents across the entire product |
| Uptake | Data specific to the dosage form used; no equation with the inhaled effect |
This overview describes the requirements for a transparent claim. It is not a recipe. Where this information is absent, the uncertainty cannot be resolved by a particularly precise scale or a longer storage log.
What applies to collection, storage, and labelling?
The library does not assess general shelf life or microbiological safety of collected already vaped bud (AVB). Blanket storage periods and assurances that visually or odour-neutral material is safe are therefore not justified. Re-use is not obligatory; the unknown residual potency and product quality should be made visible in any representation.
Clear labelling and separation from ordinary foodstuffs prevents at least accidental mix-ups. It does not replace content analysis. Unlabelled mixtures from multiple sessions additionally lose information about their origin. Editorial policy therefore derives no gram starting doses, baking recipes, or supposed safety windows from unverified anecdotal values.
What claim remains reliable?
Already heated cannabis is not chemically spent by default, but its remaining potency is undetermined. The well-documented variability of oral THC uptake compounds this uncertainty about content. A factual AVB article should explain both uncertainties rather than constructing an apparently precise set of instructions from them. Poyatos et al. (2020) Lanz et al. (2016)
Decarboxylation explains the conversion of acidic cannabinoids. Microdosing separates material quantity from active dose. The health overview contextualises the differences between exposure and health endpoints.
Frequently Asked Questions
Does AVB always retain exactly 10–30 per cent of its cannabinoids?
No. Such a general range cannot be established reliably for unknown residual samples.
Is dark-brown material practically devoid of active compounds?
That cannot be determined from colour alone. A suitable analysis would be required for any quantitative statement.
Are all acidic cannabinoids converted after a single session?
That depends on the conditions and cannot be assumed without testing.
Can the residual content be calculated from the display value?
No. The set temperature is not a complete measurement of the temperature profile and mass balance.
Source status and correction notice
Revised on 10 September 2026. Scientific reference: the linked device mass balance and the separate examination of chemical conversion. Not substantiated are general AVB potency values, colour-to-dose assignments, and complete conversion in every session. Earlier tables to that effect and recipe quantities derived from them have been removed.
Poyatos L et al. (2020)
- Study
- Systematic review of human pharmacokinetics
- Sample
- 363 hits, 26 included studies
- Comparison and measurement
- PRISMA; PubMed to March 2020; oral cannabis/THC formulations required to supply PK data including Cmax and Tmax; selection by two authors, data verification by additional authors.
- Randomisation and blinding
- Not at review level; included studies had heterogeneous designs.
- Result
- Oral THC shows delayed peak concentrations and high inter-individual as well as formulation-dependent variability; particularly variable with edibles and oils.
- Strengths
- Focused PK research question; transparent inclusion criteria; openly available.
- Limitations and potential bias
- Only PubMed searched; limited number and heterogeneous primary studies; PK is not a direct harm endpoint.
Poyatos L, Pérez-Acevedo AP, Papaseit E, Pérez-Mañá C, Martin S, Hladun O, Siles A, Torrens M, Busardo FP, Farré M. 2020. Oral Administration of Cannabis and Δ-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review. Medicina (Kaunas, Lithuania). DOI: 10.3390/medicina56060309 · PMID 32585912 · PMC7353904
Poyatos L, Pérez-Acevedo AP, Papaseit E, Pérez-Mañá C, Martin S, Hladun O, Siles A, Torrens M, Busardo FP, Farré M. 2020. Oral Administration of Cannabis and Δ-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review. Medicina (Kaunas, Lithuania). DOI: 10.3390/medicina56060309 · PMID 32585912 · PMC7353904
Lanz C et al. (2016)
- Study
- In-vitro device and aerosol validation
- Sample
- No human participants; 5 commercial dry-herb vaporizers, THC-dominant and CBD-dominant plant material.
- Comparison and measurement
- GC/MS for cannabinoid recovery in collected aerosol, HPLC for acidic cannabinoids and decarboxylation; Volcano Medic, Plenty, Arizer Solo, DaVinci, and a gas-powered device.
- Randomisation and blinding
- Not applicable.
- Result
- Electrically temperature-controlled devices decarboxylated THC/CBD very efficiently and delivered cannabinoids reproducibly; combustion was observed with the gas-powered device.
- Strengths
- Validated analytical methods; multiple devices; direct measurement of material transfer.
- Limitations and potential bias
- No human participants, no clinical endpoints, no comprehensive toxicological aerosol analysis; device generations are older.
Lanz C, Mattsson J, Soydaner U, Brenneisen R. 2016. Medicinal Cannabis: In Vitro Validation of Vaporizers for the Smoke-Free Inhalation of Cannabis. PloS one. DOI: 10.1371/journal.pone.0147286 · PMID 26784441 · PMC4718604
Lanz C, Mattsson J, Soydaner U, Brenneisen R. 2016. Medicinal Cannabis: In Vitro Validation of Vaporizers for the Smoke-Free Inhalation of Cannabis. PloS one. DOI: 10.1371/journal.pone.0147286 · PMID 26784441 · PMC4718604
Newmeyer MN et al. (2016)
- Study
- Randomised, double-blind crossover pharmacokinetics study
- Sample
- The same controlled NIDA cohort: 11 frequent and 9 occasional users (n=20).
- Comparison and measurement
- Blood PK over 54 h (occasional) and 72 h (frequent users) following smoked, vaporized, and oral cannabis.
- Randomisation and blinding
- Yes; PubMed classifies the study as an RCT, crossover, and double-blind.
- Result
- Smoked and vaporized showed relatively similar cannabinoid PK; oral cannabis produced higher THCCOOH and glucuronide concentrations and different time courses.
- Strengths
- Highly detailed PK; standardised dose; multiple routes; long sampling series.
- Limitations and potential bias
- No long-term clinical harm endpoint; same participants as several Newmeyer/Swortwood publications.
Newmeyer MN, Swortwood MJ, Barnes AJ, Abulseoud OA, Scheidweiler KB, Huestis MA. 2016. Free and Glucuronide Whole Blood Cannabinoids’ Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake. Clinical chemistry. DOI: 10.1373/clinchem.2016.263475 · PMID 27899456
Newmeyer MN, Swortwood MJ, Barnes AJ, Abulseoud OA, Scheidweiler KB, Huestis MA. 2016. Free and Glucuronide Whole Blood Cannabinoids’ Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake. Clinical chemistry. DOI: 10.1373/clinchem.2016.263475 · PMID 27899456
Monte AA et al. (2019)
- Study
- Retrospective observational study of emergency department cases
- Sample
- 9.973 cannabis-related/screened emergency department visits; 2.567 visits were attributed at least in part to cannabis.
- Comparison and measurement
- Records/ED data from Colorado; classification by inhalation versus edible exposure and clinical syndrome.
- Randomisation and blinding
- No.
- Result
- Edibles were over-represented relative to their market share and more frequently associated with acute intoxication as well as psychiatric and cardiovascular complaints; inhalation use more frequently associated with hyperemesis.
- Strengths
- Large real-world data set; direct route stratification; clinically relevant endpoints.
- Limitations and potential bias
- Retrospective; emergency department population; no clean individual exposure denominator; product dose/THC content often unknown; residual confounding.
Monte AA, Shelton SK, Mills E, Saben J, Hopkinson A, Sonn B, Devivo M, Chang T, Fox J, Brevik C, Williamson K, Abbott D. 2019. Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. Annals of internal medicine. DOI: 10.7326/M18-2809 · PMID 30909297 · PMC6788289
Monte AA, Shelton SK, Mills E, Saben J, Hopkinson A, Sonn B, Devivo M, Chang T, Fox J, Brevik C, Williamson K, Abbott D. 2019. Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. Annals of internal medicine. DOI: 10.7326/M18-2809 · PMID 30909297 · PMC6788289
Newmeyer MN et al. (2017)
- Study
- Controlled within-subject study with placebo condition
- Sample
- 20 participants: 11 frequent and 9 occasional cannabis users
- Comparison and measurement
- Placebo versus active cannabis (6.9% THC, approximately 54 mg) smoked, vaporized, or administered orally; subjective effects, heart rate, and exhaled CO.
- Randomisation and blinding
- Controlled study protocol; the same NIDA crossover cohort was described as randomised/double-blind in associated publications.
- Result
- Smoking and vaporizing increased subjective effects; heart rate rose following all active routes of administration; smoking increased CO significantly more than vaporization.
- Strengths
- Direct three-way comparison; objective CO endpoint; separate analysis of frequent and occasional users.
- Limitations and potential bias
- Very small sample; high dose; differences in tolerance; multiple publications use the same cohort and must not be counted as independent studies.
Newmeyer MN, Swortwood MJ, Abulseoud OA, Huestis MA. 2017. Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration. Drug and alcohol dependence. DOI: 10.1016/j.drugalcdep.2017.02.003 · PMID 28407543
Newmeyer MN, Swortwood MJ, Abulseoud OA, Huestis MA. 2017. Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration. Drug and alcohol dependence. DOI: 10.1016/j.drugalcdep.2017.02.003 · PMID 28407543
Newmeyer MN et al. (2017)
- Study
- Randomised controlled crossover study
- Sample
- 20 participants (11 frequent, 9 occasional users); same NIDA cohort
- Comparison and measurement
- Cannabis 6.9% THC (~50.4 mg), divided attention psychophysical field tests (Romberg, One-Leg Stand, Walk-and-Turn) and pupillometry.
- Randomisation and blinding
- Yes; ClinicalTrials.gov NCT02177513; controlled placebo, smoked, vaporizer, and oral conditions.
- Result
- In occasional users, oral cannabis was associated with a markedly increased likelihood of ≥2 impairments on OLS/WAT compared with placebo (OR 6.4; 95% CI 2.3–18.4).
- Strengths
- Controlled dose; placebo; objectively measurable performance endpoints.
- Limitations and potential bias
- Small sample; tasks assessed relatively late for inhalation conditions, which may lead to underestimation of acute effects for those routes; no long-term harms assessed.
Newmeyer MN, Swortwood MJ, Taylor ME, Abulseoud OA, Woodward TH, Huestis MA. 2017. Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration. Journal of applied toxicology : JAT. DOI: 10.1002/jat.3440 · PMID 28138971
Newmeyer MN, Swortwood MJ, Taylor ME, Abulseoud OA, Woodward TH, Huestis MA. 2017. Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration. Journal of applied toxicology : JAT. DOI: 10.1002/jat.3440 · PMID 28138971
Shared sample: The 2016 and 2017 Newmeyer publications on the three routes of administration are based on the same NIDA cohort of 20 individuals. Their findings represent different analyses and are not counted as independent samples.